Martin T. Rothman

Dr. Martin T. Rothman brings with him forty years of experience and a strong international network in the medical field.

In his role as a venture partner, Dr. Rothman focuses on helping the team identify and evaluate promising medical device companies and on mentoring entrepreneurs and physicians launching clinical innovations. Sofinnova Partners and Dr. Rothman have closely collaborated over many years. Dr. Rothman is the founder of LimFlow and an independent board member of HighLife, both portfolio companies of Sofinnova Partners.

Until recently, he was Vice President of medical affairs for coronary, structural heart and renal denervation for Medtronic, based in Santa Rosa (CA), a position he held since 2010. He was involved in the development of the renal denervation program, the Trans-Aortic Valve Replacement program, and the Medtronic percutaneous mitral regurgitation program, including Twelve and the development of its Intrepid product and associated clinical strategy.

Dr. Rothman practiced for more that 37 years in the U.K. as an interventional cardiologist, including 27 years at the London Chest Hospital (Barts and the London NHS Trust), where he has served for more than a decade as director of cardiac research and development.

He is world renowned for his contributions to clinical research, training and education, and medical technology innovation in cardiovascular medicine. A regular presenter at medical meetings and author of peer-reviewed journal articles, Dr. Rothman has conducted many clinical trials related to interventional cardiology.

As a true pioneer and leader in interventional cardiology, he has contributed to the development of numerous innovative medical technologies for interventional cardiology.

Dr. Rothman also currently holds several positions in start-up companies in the cardiovascular field, some as a founder and based on his own inventions.